Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Gains from Investment Securities (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Gains from Investment Securities for 2 consecutive years, with -$301000.0 as the latest value for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$301000.0; the TTM value through Dec 2025 reached -$71000.0, down 102.78%, while the annual FY2025 figure was -$71000.0, 102.78% down from the prior year.
  • Gains from Investment Securities was -$301000.0 for Q3 2025 at Day One Biopharmaceuticals, down from $230000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $2.6 million in Q4 2024, with the low at -$301000.0 in Q3 2025.